Edition:
United States

Agile Therapeutics Inc (AGRX.OQ)

AGRX.OQ on NASDAQ Stock Exchange Global Market

0.62USD
4:00pm EDT
Change (% chg)

$-0.05 (-6.82%)
Prev Close
$0.66
Open
$0.66
Day's High
$0.68
Day's Low
$0.61
Volume
189,155
Avg. Vol
56,368
52-wk High
$5.59
52-wk Low
$0.58

Chart for

About

Agile Therapeutics, Inc. is a women's health specialty pharmaceutical company. The Company is focused in the development and commercialization of prescription contraceptive products. The Company has developed a transdermal patch technology, called Skinfusion. The Company's lead product candidate is Twirla, also known as... (more)

Overall

Beta: 1.67
Market Cap(Mil.): $22.60
Shares Outstanding(Mil.): 34.25
Dividend: --
Yield (%): --

Financials

  AGRX.OQ Industry Sector
P/E (TTM): -- 237.88 32.90
EPS (TTM): -0.86 -- --
ROI: -73.04 -7.38 12.74
ROE: -83.42 -10.11 14.64

Agile Therapeutics sinks after FDA feedback on contraceptive

Agile Therapeutics Inc's shares sank 75 percent on Friday after the drug developer said it expects to pursue what could be a prolonged appeal against health regulators' issues over its chief experimental product, a contraceptive patch.

May 18 2018

UPDATE 2-Agile Therapeutics sinks after FDA feedback on contraceptive

* FDA suggests additional study of contraceptive may be needed

May 18 2018

Agile Therapeutics exploring funding options after FDA meeting

May 18 Agile Therapeutics Inc said on Friday it was looking for ways to fund operations after a meeting with the U.S. health regulator raised the possibility of a new clinical trial to test its stick-on contraceptive patch, Twirla.

May 18 2018

BRIEF-Agile Therapeutics Provides Regulatory Update On Twirla® (Ag200-15) For The Prevention Of Pregnancy

* AGILE THERAPEUTICS, INC. PROVIDES REGULATORY UPDATE ON TWIRLA® (AG200-15) FOR THE PREVENTION OF PREGNANCY

May 18 2018

BRIEF-Agile Therapeutics Reports Q1 Loss Per Share $0.20

* AGILE THERAPEUTICS REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS

May 07 2018

BRIEF-Agile Therapeutics Reports Q4 Loss Per Share $0.18

* AGILE THERAPEUTICS REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS

Mar 12 2018

BRIEF-Perceptive Advisors Reports 9.9 Pct Passive Stake In Agile Therapeutics

* Perceptive Advisors LLC Reports A 9.9 Pct Passive Stake In Agile Therapeutics Inc As Of Dec 22, 2017 - SEC Filing Source text: (http://bit.ly/2FlgqN8) Further company coverage:

Jan 09 2018

FDA rejects Agile's contraceptive patch, shares plunge

Agile Therapeutics Inc said on Friday the U.S. Food and Drug Administration declined to approve its contraceptive patch for the second time, sending the drug developer's shares down about 50 percent.

Dec 22 2017

UPDATE 2-FDA rejects Agile's contraceptive patch, shares plunge

Dec 22 Agile Therapeutics Inc said on Friday the U.S. Food and Drug Administration declined to approve its contraceptive patch for the second time, sending the drug developer's shares down about 50 percent.

Dec 22 2017

FDA declines to approve Agile's contraceptive patch

Dec 22 Agile Therapeutics Inc said on Friday the U.S. Food and Drug Administration declined to approve the company's contraceptive patch, citing deficiencies related to its adhesion test methods.

Dec 22 2017

Earnings vs. Estimates